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Abstract  25 
Objective.  RA typically features “rheumatoid cachexia” (loss of muscle mass (MM) and excessive 26 
fat mass (FM), especially trunk FM), which contributes to physical disability.  Since rheumatoid 27 
cachexia is driven by inflammation, it would be anticipated that the success of tight control of disease 28 
activity, such as “treat-to-target” (T2T), in attenuating inflammation would benefit body composition 29 
and physical function.  This cross-sectional study assessed the impact of T2T on body composition 30 
and objectively-assessed function in RA patients. 31 
Methods.  Eighty-two RA patients exclusively treated by T2T, were compared to 85 matched 32 
sedentary healthy controls (HC).  Body composition was estimated by DXA, with appendicular lean 33 
mass (ALM) the surrogate measure of total MM.  Physical function was assessed by knee extensor 34 
strength, handgrip strength, 30s sit-to-stands, 8’ up & go, and 50’ walk (tests which reflect the ability 35 
to perform ADLs). 36 
Results.  Although generally well treated (mean DAS28=2.8, with 49 % in ‘remission’), RA patients 37 
had ~10% proportionally less ALM and were considerably fatter (by ~27%), particularly in the trunk 38 
(~32%), than HC’s.  All measures of function were 24-34% poorer in the RA patients relative to HC. 39 
Conclusions.  Despite marked improvements in disease control (most patients achieving or 40 
approaching ‘remission’), the relative loss of MM and increased adiposity in RA patients compared 41 
to matched-HC is similar to that observed pre-T2T. Additionally, performance of objective function 42 
tests is unchanged from that reported by our group for pre-T2T RA patients.  Thus T2T, even in 43 
responsive RA patients, has not attenuated rheumatoid cachexia or improved objectively-assessed 44 
function. 45 
(249 words) 46 
47 
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Rheumatology key messages 51 
 T2T RA patients still show significant muscle loss, exacerbated adiposity and 52 
substantially impaired physical function. 53 
 Patients responding to T2T typically have the physical function of healthy individuals 54 
25 years older. 55 
 By concentrating on DAS28, T2T protocols may distract rheumatologists’ attention 56 
from physical function.  57 
 58 
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INTRODUCTION 72 
Rheumatoid arthritis (RA) is characterised by adverse changes in body composition (i.e. reduced 73 
muscle mass and increased adiposity) termed ‘rheumatoid cachexia’ [1].  Although prevalence of this 74 
condition varies according to measurement method and definition employed, muscle loss of 7.4-14.0% 75 
relative to matched healthy controls [2-5] are observed in approximately 67% of stable RA patients [3, 76 
6-15] whilst obesity, determined by body composition, is present in around 80% of stable patients [3, 77 
9-12, 16], with trunk adiposity especially prevalent [3, 8, 9-12, 17-18].  These changes in body 78 
composition, as well as exacerbating mortality and co-morbidity risk [15-19], also contribute 79 
significantly to disability [7, 20-22]. 80 
In recent years, individually tailored treatment strategies featuring early and aggressive DMARD use 81 
and frequent monitoring of treatment response to achieve low disease activity, preferably ‘clinical 82 
remission’, have been the cornerstone of pharmacologic treatment of RA.  This approach, best 83 
exemplified by ‘treat-to-target’ (T2T) [23-24], has been shown to be substantially better in controlling 84 
inflammation and arresting progression of joint damage than previous treatment strategies [23-26]. 85 
Given that rheumatoid cachexia is thought to be driven by disease activity (DA), and inflammation in 86 
particular [3, 14-15, 27], it would be anticipated that the tighter control of DA/inflammation achieved 87 
by T2T would attenuate rheumatoid cachexia and, as a consequence, reduce functional limitations in 88 
RA patients.  Pertinently, restoration of functional ability is an explicit aim of both EULAR and ACR 89 
recommendations for T2T [23-24, 28].  Although studies assessing body composition in RA patients 90 
have been performed since the widespread use of T2T (~2008), these studies [4, 6, 8, 10, 18, 20, 29-91 
31] have either exclusively or primarily used patients who commenced treatment years prior to the 92 
adoption of T2T, and therefore do not inform on the effects on body composition of T2T per se.  93 
Additionally, investigations into the impact of T2T on physical function have only used subjective 94 
instruments such as the Health Assessment Questionnaire (HAQ) [26, 32-33].  However, these 95 
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measures are strongly influenced by pain [34-35], which diminishes with T2T, and are often insensitive 96 
to changes in function in patients with controlled disease [9, 36]. 97 
Thus, we aimed to determine whether the adverse effects of RA on body composition and physical 98 
function still exist in this era of tight control of DA.  To this end, we compared body composition and 99 
objectively-assessed physical function of RA patients treated exclusively by T2T with that of age- and 100 
sex-matched healthy sedentary controls (HC).  Additionally, we compared our current findings with 101 
those previously reported by our group for stable RA patients (i.e. studies performed either before local 102 
adoption of T2T, or, if more recent, on patients who commenced treatment pre-T2T [3-4, 9-12, 30]).  103 
Lastly, this investigation sought to further examine the time-courses of rheumatoid cachexia and RA 104 
disability.  105 
 106 
METHODS  107 
This cross-sectional study was conducted between February 2013 and March 2015, with approval from 108 
the North Wales Research Ethics Committee – West (12/WA/0323), and in compliance with the 109 
Helsinki Declaration. 110 
 111 
Study population 112 
RA patients with stable disease were recruited from outpatient clinics of the Peter Maddison 113 
Rheumatology Centre (PMRC), North Wales. For inclusion, participants had to: (a) fulfil the ACR 114 
2010 revised criteria for RA [37]; (b) be aged ≥ 18 years; (c) not be cognitively impaired; (d) be free 115 
of other cachectic diseases or conditions preventing safe participation; (e) not be taking anabolic drugs 116 
or nutritional supplements; and (f) not be pregnant. Only patients who commenced DMARD treatment 117 
following the PMRC’s adoption of treatment strategies in-line with the T2T recommendations of 118 
Smolen et al [23] (i.e. post 1/1/2008) were included.  Once recruited, participants were categorised 119 
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into either ‘recent-onset’ (≤ 12 months since diagnosis) or ‘established’ (> 12 months since diagnosis) 120 
disease cohorts.  121 
 122 
For comparison, sedentary age- and sex-matched HC were recruited from the local community. To be 123 
eligible for the study, HC must have satisfied all of the inclusion criteria for RA patients, except for 124 
the diagnosis of RA. 125 
 126 
Assessments and outcome measures 127 
Participants presented for assessments in an overnight fasted state.  128 
 129 
Anthropometric and body composition measures 130 
Routine anthropometric measures (body mass (BM), height, and waist and hip circumferences) were 131 
performed using standard procedures. 132 
 133 
Total and regional lean, fat, and bone masses were estimated using a whole body fan-beam DXA 134 
scanner (Hologic, QDR Discovery 45615, software V12.4), with appendicular lean mass (ALM) used 135 
as a surrogate measure of total body muscle mass [3].  The in-house co-efficient of variation (CV) of 136 
1.4% of our scanner complies with manufacturer’s guidelines. 137 
 138 
Objective physical function 139 
Maximal isometric knee extensor strength (IKES) was measured using an isokinetic dynamometer 140 
(Humac Cybex Norm 2004, Computer Sports Medicine Inc., Massachusetts, USA) and maximal 141 
handgrip strength (HGS) by a Grip-A dynamometer (Takei Kiki Kogyo, Japan) using previously 142 
described protocols [3]. Three objective function tests, specifically developed to evaluate the capacity 143 
of older adults to perform activities of daily living (ADL [38]): ‘sit-to-stands in 30 seconds’ (STS-30), 144 
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‘8-foot up and go’ (8’UG) and ‘50-foot walk’ (50’W) tests), were also assessed. Performance of each 145 
of these strength and function tests, which are routinely used by our group [3-4, 9-12, 30-31, 39], was 146 
preceded by a submaximal practice.  147 
 148 
Clinical measures. Disease activity was assessed by the Disease Activity Score in 28 joints (DAS28) 149 
using C-reactive protein (CRP), with ‘remission’ defined as DAS28 < 2.6.  Physical disability was 150 
subjectively evaluated by the Multidimensional HAQ (MDHAQ [40]).   151 
 152 
Statistical analysis 153 
The primary outcome was ALM normalised for BM (ALM %), as this is the LM measure most relevant 154 
to performing ADL (i.e. comparing absolute ALM ignores disparities in BM and the effect fat mass 155 
(FM) has on performing ADL). The secondary outcomes included other aspects of body composition 156 
(total LM, total FM, trunk FM, and % body fat (BF%)) and the objective physical function measures. 157 
 158 
The primary statistical analyses involved comparison of the RA group versus the HC group, followed 159 
by sub-analyses of: ‘recent-onset’ versus ‘established’ RA patients; RA patients who, at the time of 160 
testing, had achieved clinical remission versus patients who had not; ‘remission’ patients versus HC; 161 
and finally, informal comparison of current results with our ‘historic’, pre-T2T data [3-4, 9-12, 30-31; 162 
patients for these studies generally commenced treatment 1992-2004]. Statistical analysis involved 163 
multiple (MANOVA) or univariate analysis of variance (ANOVA) according to appropriateness, and 164 
Chi-squared tests were used for comparison of dichotomous variables. Significance was set at P < 0.05 165 
and a trend recognised as P = 0.05 - 0.10. Data is presented as mean (±SD). 166 
 167 
RESULTS 168 
One hundred and ninety-seven (n = 197) patients with RA were deemed eligible for the study and 169 
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approached. Of these, 115 (58%) declined participation (primarily due to: ‘not interested’ or time 170 
and/or travel constraints) leaving 82 patients who were recruited.  At the time of assessment, 33 of 171 
these 82 patients had been diagnosed ≤ 12 months previously (‘recent-onset’ group; mean disease 172 
duration ~7 months), whilst the remaining 49 had a disease duration of 1-7 years (‘established’ group; 173 
mean duration ~2 years 11 months). Eighty-five age- and sex-matched sedentary HC participants were 174 
also recruited. 175 
 176 
Demographic and clinical characteristics 177 
Table 1 displays the demographic and clinical characteristics of the 82 RA patients and 85 HC 178 
participants. These groups were precisely matched for mean age (P = 0.962) and gender distribution 179 
(P = 0.992). RA patients were more frequently current (P < 0.001) or former (P < 0.001) smokers, and 180 
generally were more sedentary (P < 0.001) than the HC. For patients, the mean DAS28 score was 2.8, 181 
indicating generally ‘low DA’, and 49% had achieved a current state of ‘clinical remission’. DMARD 182 
treatment is summarised in Table 1. 183 
 184 
No differences in demographic or clinical characteristics were identified between the ‘recent-onset’ or 185 
‘established’ RA patients (data not shown), with the exception of disease duration and the proportion 186 
on combination therapy (7.1 ± 3.0 vs 34.7 ± 17.0 months, P < 0.001; and 16/33 (48%) vs 14/49 (29%), 187 
P = 0.066, respectively).  Similarly, no differences for demographic or clinical characteristics were 188 
evident between seropositive and seronegative patients (data not shown: P’s 0.625-0.905). 189 
 190 
Anthropometry and body composition  191 
Anthropometric and DXA-assessed body composition data appear in Table 2.  Despite being shorter 192 
(mean ~3cm, P = 0.019), RA patients were heavier (mean BM: +4.8 kg, P = 0.093), and consequently 193 
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their mean BMI higher (P = 0.002), than HC. RA patients also had a greater mean waist circumference 194 
(+7.7 cm, P = 0.001) and waist:hip ratio (P < 0.001) than HC. 195 
  196 
When adjusted for BM (i.e. % of), RA patients had ~10% less muscle than HC (ALM %, P < 0.001).  197 
This relative deficit corresponds with the proportional loss of ALM we observed in stable RA patients, 198 
of similar age and gender distribution, who had commenced treatment ~1992-2004 (i.e. ~9%, RA n = 199 
23, matched HC, n = 23 [4]; ~11%, RA n = 20, matched HC, n = 20 [3]).  When expressed absolutely 200 
(kg), RA patients in the current study exhibited less ALM (-1.1 kg) and TLM (-0.8 kg) than the HC, 201 
although these differences were not statistically significant. 202 
 203 
DXA-assessed body composition confirmed that RA patients were considerably fatter than HC, with 204 
the group differences in BM more than accounted for by higher total FM in patients (+5.4 kg, 26.5% 205 
greater, P < 0.001).  Consequently, BF% was also higher in patients (P < 0.001).  As anticipated, the 206 
majority of this increased adiposity was situated on the trunk (+3.2 kg, 32.3% higher than HC, P = 207 
0.001). In pre-T2T patients we had noted mean increases in total FM of ~17% [4] and ~13% [3] relative 208 
to HC. 209 
 210 
No differences in anthropometric or DXA measures were evident between the ‘recent-onset’ and 211 
‘established’, or between seropositive and seronegative, RA patients (data not shown; P’s = 0.581-212 
0.998).  213 
 214 
Objective physical function 215 
Compared with HC, RA patients performed poorly in each of the objective function measures (Table 216 
3): IKES was 24.3% less (P < 0.001); HGS, 25.3% less (P < 0.001); STS-30, 34.2% less (P < 0.001); 217 
8’UG, 31.1% slower (P < 0.001); and 50’W, 28.0% slower (P < 0.001). The absolute levels of 218 
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performance for those tests not subject to equipment changes (i.e. STS-30, 8’UG, 50’ W), achieved by 219 
RA patients in the current study are not an improvement on those we observed in stable pre-T2T RA 220 
patients (STS-30: mean range 10.9 – 14.7 repetitions, overall mean = 12.4 (vs 12.0 repetitions in the 221 
current study) [3-4, 9-12, 30-31]; 8’UG: mean range 6.0 – 6.4 secs, overall mean = 6.2 (vs 7.4 secs) 222 
[4, 30-31]; 50’W mean range 9.1 – 10.0 secs, overall mean = 9.5 (vs 10.7 secs) [4, 9-10, 30-31]. 223 
 224 
As with the anthropometric and body composition measures, there were no differences in performance 225 
for any of the objective function tests between the ‘recent-onset’ and ‘established’ RA patients (data 226 
not shown; P’s = 0.435-0.778). 227 
 228 
Subjective measures of disability and health 229 
As expected, RA patients had higher MDHAQ scores than the HC group (P = 0.001; Table 1). Despite 230 
the marked impairments in objectively-assessed physical function relative to HC, the RA patients 231 
subjectively regarded themselves as only ‘mildly disabled’ (Table 1). There was no difference in 232 
MDHAQ scores between ‘recent-onset’ and ‘established’ RA patients (data not shown, P = 0.880). 233 
 234 
‘Remission’ versus ‘non-remission’ RA patients 235 
Of the 82 RA patients, 40 had achieved clinical remission at the time of assessment (DAS28: 2.0 ± 236 
0.4).  There were no differences in age, seropositivity, disease duration or medication between 237 
‘remission’ and ‘non-remission’ patients, however, proportionally fewer females achieved ‘remission’ 238 
(58% vs 71%, P = 0.187) (Table 4). 239 
 240 
In comparison to those not in remission (DAS28: 3.6 ± 0.8), the ‘remission’ patients generally had 241 
slightly better body composition, albeit not significantly (Table 5), and performed the function tests 242 
better (Table 6).  However, even in this subgroup of highly responsive patients, body composition (i.e. 243 
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waist circumference, P = 0.039; waist:hip ratio, P < 0.001; ALM, P = 0.003; ALM%, P < 0.001; total 244 
FM, P = 0.014; BF%, P = 0.001; trunk FM, P = 0.017) and objectively-assessed function (relative 245 
deficits of 13 – 31%; IKES, P = 0.002; HGS, P < 0.001; STS-30, P < 0.001; 8’UG, P = 0.008; 50’W, 246 
P = 0.014) were still much worse than for HC.   247 
 248 
DISCUSSION 249 
This is the first investigation of the effects on body composition and objectively-assessed physical 250 
function of current treatment regimens which aim to tightly control DA in RA patients. Overall the 251 
findings show that our T2T RA patients, including those who have achieved clinical remission, 252 
continue to have substantially reduced muscle mass, much greater levels of adiposity (especially 253 
trunk), and considerably worse function than sedentary age- and sex-matched healthy individuals. 254 
These adverse effects are despite a mean DAS28 of 2.8 (an ‘acceptable alternative therapeutic goal’ 255 
[23-24]) and achievement of ‘clinical remission’ in approximately half our patients, both of which 256 
indicate that our cohort is well-treated and generally benefiting from the T2T approach.   257 
 258 
Whilst the precise mechanisms underlying rheumatoid cachexia remain unclear, disease activity (i.e. 259 
inflammation) is widely accepted to be the primary driver [1, 13, 27, 29, 41]. Hence, it would be 260 
anticipated that the success of T2T in suppressing inflammation would be reflected in improved body 261 
composition in RA patients treated exclusively by this strategy relative to patients who received 262 
earlier, less clinically effective treatments.  However, the proportional loss of muscle mass of ~10 % 263 
observed in our current patients relative to matched, sedentary healthy controls is similar to what we 264 
had noted in stable, pre-T2T RA patients (~9%, for patients with a mean RA Disease Activity Index 265 
(RADAI) = 3.1 ± 0.3 [4]; and ~11%, for patients with RADAI = 2.65 ± 1.4 [3]).  This current deficit 266 
is also in line with the DXA-assessed ALM/BM% differences between controlled pre-T2T patients 267 
and healthy individuals described by others; i.e. 12% [5], 8% [42], 9% [43] (data collection 2004-268 
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2006), 11% in women and 10% in men [2] (RA patients diagnosed 1995-2001) and in the follow-up 269 
to the last study, 11% in women and 7% in men [44].  Additionally, Elkan et al [7] (data collection 270 
2004-2005) found an 11% reduction in DXA-assessed fat free mass index (FFM/height (m)2) of RA 271 
patients with active disease (mean DAS28 = 5.5) versus a matched European reference population.   272 
 273 
The elevated adiposity we observed in our T2T RA patients relative to sedentary controls (FM (kg) 274 
increased by 26.5%, BF% increased 15.5%, trunk FM increased 32.3%) is also consistent with the 275 
observations made in our pre-T2T RA patients (total FM increases of ~17% [4] and ~13% [3] versus 276 
HC), and generally with the DXA-assessed disparities in adiposity reported by others in stable, pre-277 
T2T RA patients relative to matched HC (FM (kg) increased by 12% [5]; FM and trunk FM 278 
increased 13% and 25%, respectively [43]; FM and trunk FM increased 12.5% and 13.5% in 279 
females, and 5.4% and 7.1% in males, respectively [42]; FM and trunk FM increased 13.5% and 280 
21.6%, respectively, in females, with no additional adiposity in males [2]; and FM and trunk FM 281 
increased 15.3% and 19.4%, respectively, in females, with no additional adiposity in males [44]). 282 
Whilst the RA patients in the current study were more sedentary than the HC, the between-group 283 
difference only amounted to approximately 30 minutes walking/week, and both groups fall well short 284 
of the minimum recommendation for long-term loss of FM of 250 min/week of moderate intensity 285 
physical activity (PA) [45].  This 30 minute disparity in low-moderate intensity PA would also not 286 
account for the difference in MM, as higher-intensity exercise is required to elicit hypertrophy [45]. 287 
Thus, our findings clearly indicate that rheumatoid cachexia has not been resolved, or even 288 
attenuated, by tight control of DA, despite the other clinical benefits this approach confers. 289 
 290 
We also demonstrated in this study that objectively-assessed physical function has not improved with 291 
T2T therapy.  This finding is not surprising in view of the lack of improvement in either muscle or 292 
fat masses, and the strong association between these and physical function in RA patients [16, 20-293 
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22]. In our T2T patients, strength relative to health controls was reduced by ~25% and the 294 
performance level of tests designed to reflect the ability to perform ADL and live independently [38], 295 
reduced by about a third.  More tellingly with regard to the effect of T2T on function, the test scores 296 
obtained by patients in the current study were not better, and in some cases were worse (8’UG, 297 
50’W), than those of patients in our earlier studies [3-4, 9-12, 30-31] who were of similar age and 298 
gender distribution.  To provide a context of how poor the physical function of our T2T RA patients 299 
is, Rikli and Jones [38] recently published minimal fitness standards compatible with living 300 
independently late in life using objective tests (including STS-30 and 8’UG).  In the present study, 301 
the RA women (mean age 58.6 years) achieved a STS-30 score appropriate for healthy ‘moderate 302 
functioning’ women aged 80-84 years, and the RA men (mean age of 65.0 years) a score in line with 303 
healthy ‘moderate functioning’ men of 85-89 years. For the 8’UG test, the respective equivalents 304 
were 85-89 years for the women, and the men failed to achieve the standard of 90-94 year old 305 
healthy men (the highest age category).  Hence, on average, both the female and male patients had 306 
the function of healthy individuals approximately 25 years older.   307 
 308 
Despite the substantial deficits in objectively-measured physical function (28-34% worse than 309 
sedentary HC), it is revealing that the patients generally rated their disability as only being ‘mild’ 310 
(mean MDHAQ = 0.57).  Also of interest, is that our earlier (pre-T2T) patients, although generally 311 
performing the objective tests as well, if not better than, the recent T2T patients, subjectively rated 312 
their disability as being higher (e.g. data collected 2005-2007, baseline means; DAS28 = 3.3, STS30 313 
= 12.5 reps, 50’W = 9.3 secs, IKES = 323 N, MDHAQ = 0.91 [9]).  This improvement in 314 
subjectively-assessed function (e.g. HAQ, MDHAQ) with T2T has been widely reported [26, 32-33] 315 
and may be due to reductions in pain [25], as pain is known to strongly influence HAQ scores [34-316 
35, 46]. This discord between objectively- and subjectively-assessed function in stable RA patients, 317 
together with the underestimation RA patients have of their disability, highlights the value of 318 
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objective function tests and provides further evidence of their greater sensitivity for detecting 319 
functional change in patients with well-controlled disease [9, 36].  320 
 321 
A key aim of T2T is “normalisation of function” (e.g. “Overarching principal” B; 322 
EULAR/International Task Force Recommendations [23-24]; ACR [28]). Our findings indicate that 323 
T2T has made inadequate progress in achieving this, even for patients achieving ‘remission’ (DAS28 324 
= 2.0 ± 0.4; whose performance of function tests was approximately 1/5th – 1/3rd poorer than sedentary 325 
HC). Additionally, we may have underestimated the extent of functional loss (and the perturbations in 326 
body composition) existing in broader RA populations as low DA and a high remission rate were 327 
achieved for our patients primarily with DMARD monotherapy, and no recourse to biologics, 328 
indicating that our cohort generally has mild-moderate, and responsive, disease. 329 
 330 
Another point to raise is the failure of widely-used measures of treatment efficacy for T2T (e.g. 331 
DAS28) to assess function, either objectively or subjectively, which is counter to both the 332 
prominence that restoration of physical function has amongst the goals of this treatment, and the 333 
strong associations function has with morbidity, mortality, treatment costs and patient quality of life 334 
in RA [47]. 335 
 336 
An obvious question arising from our results is why has T2T failed to improve body composition and, 337 
consequently, physical function, given its beneficial effects on inflammation and DA, the purported 338 
drivers of rheumatoid cachexia?  A likely explanation is that the perturbations in body composition 339 
predominantly occur very early in the disease (i.e. during the ‘pre-clinical’ stage), and thus prior to the 340 
initiation of treatment. This proposal is consistent with: i) the absence of differences in anthropometric, 341 
body composition, or physical function measures between our ‘recent’ and ‘established’ RA patients; 342 
ii) reports of a similar incidence and magnitude of rheumatoid cachexia in recently diagnosed RA 343 
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patients as for established patients [2, 12]; iii) indications that the rate of muscle loss in established, 344 
controlled patients is similar to that of healthy individuals [10, 44]; and iv) the consistent findings that 345 
disease processes, including inflammation and co-morbidity risk are already elevated in the pre-clinical 346 
period [48]. 347 
 348 
To summarise, our study shows that T2T, despite its enhanced efficacy in reducing DA, inflammation 349 
and joint damage, has not improved patients’ body composition or physical function relative to 350 
previous treatment regimens.  As a consequence, RA patients remain significantly muscle wasted and 351 
fatter, and this, at least in part, accounts for why they have substantially impaired function relative to 352 
healthy individuals.  Unfortunately, these important adverse consequences of RA are usually neglected 353 
as the T2T regimen posits that DAS28 score should be the clinician’s primary concern.  Consequently, 354 
in this pharmacological model of treatment, focus on the need for rehabilitation has diminished.  The 355 
inclusion of an objective function test(s) during clinical reviews of DA would highlight to both the 356 
rheumatologist and the patient the need for adjunct treatments, such as high intensity exercise 357 
(especially resistance training [3, 9] and nutritional supplementation [11, 49-50], that specifically aim 358 
to restore body composition and physical function in RA patients.  359 
Words: 3495 360 
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TABLE 1. Demographic and clinical characteristics for rheumatoid arthritis patients and 551 
sedentary, age- and sex-matched health controls 552 
 RA (n = 82) HC (n = 85) P 
Age (years)  60.9 (±11.7) 60.9 (±8.1) 0.962 
Sex (n female) (%) 53 (65) 55 (65) 0.992 
Disease duration (months) 23.8 (±19.0) - - 
Seropositive RA; n (%) 67 (85) - - 
DAS28 (0-10) 2.8 (1.0) - - 
Medications, n (%) 
Methotrexate a 68 (83) - - 
Hydroxychloroquine 26 (32) - - 
Leflunomide 7 (9) - - 
Sulfasalazine 5 (6) - - 
Tacrolimus 3 (4) - - 
Mycophenolate mofetil 1 (1)   
Biologic  0 (0) - - 
Mono-DMARD therapy 48 (59)   
Combination DMARDs b 30 (37) - - 
No DMARD 3 (4)   
Corticosteroids c 7 (9) 1d (1) 0.026* 
Analgesics/NSAIDs 44 (54) 8 (9) < 0.001* 
Smoking status, n (%) 
Current smokers; n (%) 18 (22) 3 (5) < 0.001* 
Ex-smokers; n (%) 39 (48) 25 (31) < 0.016* 
Never smokers; n (%) 25 (30) 52 (61) < 0.001* 
25 
 
Subjective measure of disability 
MDHAQ score (/3) 0.57 (±0.54) 0.08 (±0.24) 0.001* 
Exercise frequency e, n (%)    
Exercise frequency score (0-3) 1.1 (±1.3) 2.2 (±1.0) < 0.001* 
Do not regularly exercise (0) 43 (52) 9 (11) < 0.001* 
1-2 times a month (1) 6 (8) 7 (8) 0.825 
1-2 times a week (2) 11 (14) 27 (32) 0.005* 
>3 times a week (3) 20 (25) 41 (49) 0.001* 
 553 
Unless stated, data presented as mean (±SD). Differences at baseline were assessed using analyses of 554 
variance or Chi-square test as appropriate. RA = rheumatoid arthritis; HC = healthy control group; 555 
Seropositive RA = rheumatoid factor and/or anti-CCP seropositive; DAS28 = Disease Activity Score 556 
in 28 joints; a = supplemented with folate; DMARD = disease modifying anti-rheumatic drug; b = 557 
double or triple DMARD therapy; c = current corticosteroid range 5.0 – 10.0 mg/d; d = corticosteroid 558 
inhaler for asthma; NSAID = non-steroidal anti-inflammatory drug; MDHAQ = multi-dimensional 559 
health assessment questionnaire; e = self-reported exercise frequency taken from MDHAQ (not 560 
reported: RA = 2, HC = 1); Exercise frequency score: 0 = no regular exercise; 1 = 1-2 times a month; 561 
2 = 1-2 times a week; 3 = >3 times a week; unless adjusted by Bonferroni adjustment * = significant 562 
(P < 0.05). 563 
 564 
 565 
 566 
 567 
 568 
 569 
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TABLE 2. Body composition measures for rheumatoid arthritis patients and sedentary, age- and 570 
sex-matched health controls  571 
 
RA 
(n = 82) 
HC 
(n = 85) 
% difference  
 (CI for absolute 
difference) 
P 
Waist circ. (cm) 91.6 (±17.9) 83.9 (±10.8) ↑ 8.4 (3.2 – 12.2) 0.001* 
Hip circ. (cm) 101.9 (±12.7) 99.1 (±7.8) ↑ 2.7 (-0.4 – 6.1) 0.128 
Waist: hip ratio 0.90 (±0.10) 0.85 (±0.08) ↑ 5.6 (0.0 – 0.1) < 0.001* 
BM (kg) 
Height (cm)  
76.5 (17.9) 
165.1 (±7.9) 
71.7 (±11.1) 
168.1 (±8.6) 
↑ 6.3 (0.2 – 9.3) 
↓ 3.0 (0.5 – 5.5) 
0.093# 
0.019* 
BMI (kg/m2) 28.0 (±6.0) 25.4 (±3.4) ↑ 9.3 (-4.1 - -1.2) 0.002* 
DXA-assessed measures 
ALM (kg) 19.8 (±4.6) 20.9 (±5.2) ↓ 5.6 (-0.4 – 2.6) 0.158 
ALM % (ALM/TBM %) 26.2 (±4.0) 28.8 (±4.2) ↓ 9.9 (1.4 – 3.9) < 0.001* 
Total LM (kg) 48.7 (±9.8) 49.5 (±10.0) ↓ 1.6 (-2.2 – 3.9) 0.578 
TLM % (LM/BM %) 64.4 (±7.5) 68.6 (±6.8) ↓ 6.5 (1.9 – 6.3) < 0.001* 
Total FM (kg) 25.8 (±10.4) 20.4 (±6.2) ↑ 26.5 (-7.9 - -2.7) < 0.001* 
BF% 32.7 (±7.8) 28.3 (±7.2) ↑ 15.5 (2.1 – 6.7) < 0.001* 
Trunk FM (kg) 13.1 (±6.3) 9.9 (±3.7) ↑ 32.3 (1.6 – 4.8) 0.001* 
 572 
Data presented as mean (±SD). CI = 95 % confidence interval; RA = rheumatoid arthritis; HC = healthy 573 
control group; BM = body mass; BMI = body mass index; DXA = dual energy x-ray absorptiometry; 574 
ALM = appendicular lean mass; TLM = total lean mass; FM = fat mass; BF% = % body fat (i.e. 575 
FM/BM x 100); unless adjusted by Bonferroni adjustment * = significant (P < 0.05), # = trend (P = 576 
0.05 - 0.10). 577 
578 
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TABLE 3. Objective physical function and self-reported disability for rheumatoid arthritis 579 
patients and sedentary, age- and sex-matched health controls  580 
 RA  
(n = 82) 
HC 
(n = 85) 
Absolute difference 
(% difference) (CI) 
P 
IKES (N) 380 (±140) 472 (±152) ↓ 92 (24.3) (46 – 138) < 0.001* 
HGS (kg) 26.5 (±8.8) 33.2 (±9.9) ↓ 6.7 (25.3) (3.8 – 9.7) < 0.001* 
STS-30 test (reps) 12.0 (±3.6) 16.1 (±4.3) ↓ 4.1 (34.2) (2.8 – 5.3) < 0.001* 
8’UG (secs) 7.4 (±3.9) 5.1 (±1.0) ↑ 2.3 (31.1) (1.4 – 3.1) < 0.001* 
50’W (secs) 10.7 (±5.3) 7.7 (±1.8) ↑ 3.0 (28.0) (1.8 – 4.3) < 0.001* 
 581 
Data presented as mean (±SD). CI = 95 % confidence interval; RA = rheumatoid arthritis; HC = healthy 582 
control group; IKES = isometric knee extensor strength; HGS = handgrip strength; STS-30 = Sit-to-583 
stands in 30 seconds; 8’UG = 8-foot up and go; 50’W = 50-foot walk: unless adjusted by Bonferroni 584 
adjustment * = significant (P < 0.05). 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
 596 
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TABLE 4. Demographic and clinical characteristics for rheumatoid arthritis patients in ‘remission’ (DAS28 < 2.6) or not (DAS28 ≥ 2.6) 597 
 ‘In remission’ vs ‘Not in remission’ HC vs ‘In remission’ 
 ‘In remission’ (n = 40) ‘Not in remission’ (n = 42) P HC (n = 85) P 
Age (years)  60.4 (±12.2) 61.4 (±11.3) 0.706 60.9 (±8.1) 0.764 
Sex (n female) (%) 23 (58) 30 (71) 0.187 55 (65) 0.435 
Disease duration (months) 23.1 (±17.5) 24.5 (±20.6) 0.740 - - 
Serpositive RA; n (%) 32 (80) 35 (83) 0.886 - - 
DAS28 (0-10) 2.0 (±0.4) 3.6 (±0.8) < 0.001* - - 
CRP (mg/L) 7.3 (±7.7) 13.1 (±14.4) 0.024* - - 
Medications, n (%)   
Methotrexate a 34 (85) 34 (81) 0.626 - - 
Hydroxychloroquine 3 (8) 2 (5) 0.604 - - 
Leflunomide 3 (8) 4 (10) 0.743 - - 
Sulfasalazine 13 (33) 13 (31) 0.880 - - 
Tacrolimus 1 (3) 1 (2) 0.972 - - 
Mycophenolate mofetil 0 (0) 1 (2) - - - 
Biologic  0 (0) 0 (0) - - - 
Mono-DMARD therapy 24 (60) 25 (60) 0.930 - - 
Combination DMARDs b 15 (38) 15 (36) 0.930 - - 
No DMARD 1 (3) 2 (5) 0.586 - - 
Corticosteroids c 3 (8) 4 (10) 0.743 1 d (1) 0.061* 
Analgesics/NSAIDs 16 (40) 28 (67) 0.015* 8 (9) < 0.001* 
29 
 
Smoking status, n (%)      
Current smokers; n (%) 7 (18) 11 (26) 0.180 3 (5) 0.014* 
Ex-smokers; n (%) 19 (48) 20 (48) 0.493 25 (31) 0.007* 
Never smokers; n (%) 14 (35) 11 (26) 0.542 52 (61) 0.001* 
Subjective measure of disability 
MDHAQ score (/3) 0.32 (±0.32) 0.81 (±0.59) < 0.001* 0.08 (±0.04) 0.001* 
Exercise frequency e, n (%)      
Exercise frequency score (0-3) 1.1 (±1.3) 1.2 (±1.3) 0.733 2.2 (±1.0) < 0.001* 
Do not exercise (0) 22 (55) 21 (50) 0.733 7 (8) < 0.001* 
1-2 times a month (1) 4 (10) 2 (5) 0.363 7 (8) 0.745 
1-2 times a week (2) 4 (10) 7 (18) 0.376 27 (32) 0.009* 
>3 times a week (3) 10 (25) 10 (25) 0.900 41 (49) 0.014* 
 598 
Unless stated, data presented as mean (±SD). Differences at baseline were assessed using analyses of variance or Chi-square test as appropriate. 599 
Seropositive RA = rheumatoid factor and/or anti-CCP seropositive; DAS28 = Disease Activity Score in 28 joints; a = supplemented with folate; 600 
DMARD = disease modifying anti-rheumatic drug; b = double or triple DMARD therapy; c = current corticosteroid range 5.0 – 10.0 mg/d; d = 601 
corticosteroid inhaler for asthma; NSAID = non-steroidal anti-inflammatory drug; MDHAQ = multi-dimensional health assessment questionnaire; 602 
e = self-reported exercise frequency taken from MDHAQ (not reported: RA = 2, HC = 1); Exercise frequency score: 0 = no regular exercise; 1 = 603 
1-2 times a month; 2 = 1-2 times a week; 3 = >3 times a week; unless adjusted by Bonferroni adjustment * = significant (P < 0.05); # = trend (P = 604 
0.05 - 0.10). 605 
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 606 
TABLE 5. Body composition measures for rheumatoid arthritis patients in ‘remission’ (DAS28 < 2.6) or not (DAS28 ≥ 2.6) 607 
 ‘In remission’ vs ‘Not in remission’ HC vs ‘In remission’ 
 ‘In remission’ 
(n = 40) 
‘Not in remission’ 
(n = 42) 
Absolute difference 
(CI) 
P P¥ HC (n = 85) 
Absolute 
difference (CI) 
P¥ 
Waist circ. (cm) 90.3 (±16.5) 92.9 (±19.2) -2.6 (-10.5 – 5.3) 0.514 0.258 83.9 (±10.8) -6.4 (-10.7– - 0.3) 0.039* 
Hip circ. (cm) 100.0 (±10.0) 103.8 (±14.7) -3.9 (-9.4 – 1.7) 0.169 0.246 99.1 (±7.8) -0.9 (-5.1 – 2.9) 0.592 
Waist: hip ratio 0.90 (±0.12) 0.90 (±0.09) 0.00 (-0.05 – 0.04) 0.949 0.139 0.85 (±0.08) -0.05 (-0.07- -
0.02) 
< 0.001* 
BM (kg) 
Height (cm) 
74.9 (±17.7) 
166.0 (±8.2) 
78.0 (±18.2) 
164.2 (±8.2) 
-3.2 (-11.1 – 4.7) 
-1.8 (-5.5. – 1.7) 
0.425 
0.287 
0.183 
0.306 
71.7 (±11.1) 
168.1 (±8.6) 
-3.2 (-7.3 – 2.9) 
2.1 (-1.1 – 5.2) 
0.397 
0.195 
BMI (kg/m2) 27.0 (±5.1) 29.0 (±6.7) -2.0 (-4.6 – 0.7) 0.143 0.133 25.4 (±3.4) -1.6 (-3.4 – 0.2) 0.084# 
DXA-assessed measures 
ALM (kg) 19.7 (±4.6) 19.9 (±4.6) -0.1 (-2.2 – 1.9) 0.905 0.148 20.9 (±5.2) 1.2 (0.6 – 2.8) 0.003* 
ALM % (ALM/TBM %) 26.9 (±3.9) 25.5 (±3.9) 1.3 (-0.4 – 3.1) 0.122 0.347 28.8 (±4.2) 1.9 (1.2 – 3.5) < 0.001* 
TLM (kg) 48.2 (±9.4) 49.2 (±10.3) -1.0 (-5.4 – 3.4) 0.650 0.071# 49.5 (±10.0) 1.3 (-0.2 – 4.6) 0.052# 
Total LM % (LM/TBM %) 65.5 (±6.6) 63.3 (±8.0) 2.2 (-1.0 – 5.5) 0.179 0.458 68.6 (±6.8) 3.1 (1.5 – 5.8) 0.001* 
Total FM (kg) 24.2 (±9.2) 27.3 (±11.3) -3.1 (-7.7 – 1.4) 0.176 0.241 20.4 (±6.2) -3.8 (-7.1 - -0.8) 0.014* 
BF% 31.5 (±7.0) 33.8 (±8.5) -2.4 (-5.8 – 1.0) 0.170 0.434 28.3 (±7.2) -3.2 (-6.1 - -1.5) 0.001* 
Trunk FM (kg) 12.2 (±6.1) 13.9 (±6.4) -1.6 (-4.4 – 1.1) 0.242 0.252 9.9 (±3.7) -2.3 (-4.3 - -0.4) 0.017* 
 608 
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Data presented as unadjusted mean (±SD). CI = 95 % confidence interval; RA = rheumatoid arthritis; HC = healthy controls; BM = body mass; 609 
BMI = body mass index; DXA = dual x-ray absorptiometry; ALM = appendicular lean mass; TLM = total lean mass; FM = fat mass; BF% = % 610 
body fat (i.e. FM/BM x 100); unless adjusted by Bonferroni adjustment * = significant (P < 0.05); # = trend (P = 0.05 - 0.10); P¥ = adjusted 611 
significance value when sex included as co-variant due to a difference in the proportion of males to females.   612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
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TABLE 6. Objective physical function and self-reported disability for rheumatoid arthritis in ‘remission’ (DAS28 < 2.6) or not (DAS28 623 
≥ 2.6) 624 
 ‘In remission’ vs ‘Not in remission’ HC vs ‘In remission’ 
 
‘In remission’ 
(n = 40) 
‘Not in 
remission’  
(n = 42) 
Absolute difference 
(CI) 
P P¥ HC (n = 85) 
Absolute difference 
(CI) 
P¥ 
IKES (N) 414 (±141) 343 (±130) 71 (10 – 132) 0.023* 0.052# 477 (±155) 62 (26 - 117) 0.002* 
HGS (kg) 29.6 (±8.3) 22.9 (±9.3) 6.6 (2.7 – 10.5) 0.001* 0.002* 33.4 (±10.0) 3.8 (2.4 – 7.4) < 0.001* 
STS-30 test (reps) 12.3 (±3.3) 11.7 (±3.9) 0.5 (-1.1 – 2.1) 0.513 0.459 16.1 (±4.3) 3.8 (2.3 – 5.3) < 0.001* 
8’UG (secs) 6.6 (±2.1) 8.2 (±4.9) -1.6 (-3.3 – 0.1) 0.057# 0.042* 5.1 (±1.0) -1.5 (-2.5 - -0.4) 0.008* 
50’W (secs) 9.5 (±2.4) 11.9 (±6.8) -2.3 (-4.6 - - 0.1) 0.042* 0.037* 7.7 (±1.8) -1.8 (-3.3 - -0.4) 0.014* 
 625 
Data presented as unadjusted mean (±SD). CI = 95 % confidence interval; RA = rheumatoid arthritis; HC = healthy controls; IKES = isometric 626 
knee extensor strength; HGS = handgrip strength; STS-30 = Sit-to-stands in 30 seconds; 8’UG = 8-foot up and go; 50’W = 50-foot walk; unless 627 
adjusted by Bonferroni adjustment * = significant (P < 0.05); # = trend (P = 0.05 - 0.10); P¥ = adjusted significance value when sex included as 628 
co-variant due to a difference in the proportion of males to females.  629 
 630 
